Risk of Retinal Detachment After Intravitreal Injection of Anti-VEGF: A Systematic Review and Meta-Analysis.

Am J OphthalmolJun 1, 2026 (epub)
Clinical ResearchOphthalmology

David Mikhail, Brendan K Tao, Philip Yu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed the risk of retinal detachment (RD) following intravitreal injections of anti-VEGF agents across various conditions. Analyzing data from 12 studies with 834,814 injections, the pooled risk of rhegmatogenous RD was found to be 0.012% (1 in 8675 injections).

Key findings

  • Pooled risk of rhegmatogenous RD was 0.012% (1 in 8675 injections) across 9 studies.
  • Acute postprocedural risk (≤90 days) was 0.013% (1 in 7692 injections).
  • Per-eye risk of RD was 0.08% (1 in 1250 eyes).
  • One study reported tractional RD risk as 3.6% (1 in 28 injections) in severe PDR cases.

Why it matters

Understanding the low risk of retinal detachment after anti-VEGF injections helps clinicians provide informed consent and manage patient expectations regarding this common procedure.

Source

PubMed · PMID 42219076

Published in Am J Ophthalmol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.